Protagonist Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTGX-US : November 20, 2017 Mon, 20 Nov 2017 12:25:03 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Protagonist Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Protagonist Therapeutics, Inc. – Value Analysis (NASDAQ:PTGX) : November 10, 2017 Fri, 10 Nov 2017 18:24:21 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Protagonist Therapeutics, Inc. a score of 40. Our analysis is based on comparing Protagonist Therapeutics, Inc. with the following peers – Plandai Biotechnology, Inc., Pieris Pharmaceuticals, Inc., PDL BioPharma, Inc. and Bioblast Pharma Ltd. (PLPL-US, PIRS-US, PDLI-US and ORPN-US). Investment Outlook Protagonist Therapeutics, Inc. has a fundamental ... Read more
(Read more...)
Protagonist Therapeutics posts 3Q loss Mon, 06 Nov 2017 21:21:49 +0000 The Malpitas, California-based company said it had a loss of 29 cents per share. The biopharmaceutical company posted revenue of $8.8 million in the period. Protagonist Therapeutics shares have dropped ...
Protagonist Therapeutics to Present at the Stifel 2017 Healthcare Conference Wed, 01 Nov 2017 20:17:00 +0000 NEWARK, Calif. , Nov. 1, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel , Ph.D., the company's President and Chief Executive Officer, will provide ...
Protagonist Therapeutics Prices Public Offering of Common Stock Thu, 12 Oct 2017 02:25:00 +0000 NEWARK, Calif., Oct. 11, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX), a biopharmaceutical company that discovers and develops novel peptide-based drugs, announced today that it has priced an underwritten public offering of 3,530,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to Protagonist from the offering, before underwriting discounts and commissions and offering costs, are expected to be $60,010,000. Protagonist has granted the underwriters a 30-day option to purchase up to an additional 529,500 shares of common stock.
Protagonist Therapeutics Announces Proposed Public Offering of Common Stock Wed, 11 Oct 2017 20:01:00 +0000 NEWARK, Calif., Oct. 11, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX), a biopharmaceutical company that discovers and develops novel peptide-based drugs, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Protagonist also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. All of the shares to be sold in the offering are to be sold by Protagonist.
Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 Wed, 20 Sep 2017 12:00:00 +0000 NEWARK, Calif., Sept. 20, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced preliminary results from the Phase 1 study of PTG-300 in normal healthy volunteers. PTG-300 is an injectable hepcidin mimetic peptide, discovered using the company's proprietary technology platform. Protagonist is developing PTG-300 as a potential treatment for patients with ineffective erythropoiesis in rare diseases such as beta-thalassemia and myelodysplastic syndromes (MDS).
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 0.73 (median winner: 1.53)
Above 40wkMA: 47% (median winner: 35%)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.